SureTrader Advertisement
Home > Boards > US Listed > Medical - Drugs > Momenta Pharmaceuticals, Inc. (MNTA)

MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
floblu14 Member Profile
Member Level 
Followed By 18
Posts 2,496
Boards Moderated 0
Alias Born 07/20/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/24/2016 3:26:43 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 6/24/2016 2:26:16 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/23/2016 8:17:03 AM
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors "GlobeNewswire Inc." - 6/23/2016 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/22/2016 4:17:50 PM
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody "GlobeNewswire Inc." - 6/9/2016 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/8/2016 3:56:51 PM
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab) Biosimilar, at EULAR 2016 "GlobeNewswire Inc." - 6/8/2016 8:00:00 AM
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Ca... "GlobeNewswire Inc." - 6/4/2016 9:00:00 AM
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference "GlobeNewswire Inc." - 5/25/2016 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/23/2016 4:45:29 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/23/2016 4:18:27 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/23/2016 12:50:22 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/23/2016 12:48:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/23/2016 12:44:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/23/2016 12:41:33 PM
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting "GlobeNewswire Inc." - 5/19/2016 8:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/6/2016 5:56:51 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/3/2016 8:12:27 AM
Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results "GlobeNewswire Inc." - 5/3/2016 8:00:00 AM
Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference Call and Webcast "GlobeNewswire Inc." - 4/28/2016 11:46:12 AM
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences "GlobeNewswire Inc." - 4/28/2016 11:46:04 AM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 4/27/2016 4:47:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/19/2016 4:12:42 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/19/2016 4:10:31 PM
floblu14 Member Level  Wednesday, 12/07/11 09:36:20 AM
Re: None
Post # of 15653 
MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

MOMENTA PHARMACEUTICALS, INC., Plaintiff-Appellee, and
SANDOZ, INC., Plaintiff-Appellee,
v.
AMPHASTAR PHARMACEUTICALS, INC., INTERNATIONAL MEDICATION SYSTEMS, LTD., WATSON PHARMACEUTICALS, INC. and WATSON PHARMA, INC., Defendants-Appellants.

Nos. 2012-1062, 2012-xxxx, 2012-xxxx

United States Court of Appeals, Federal Circuit.


December 6, 2011.


This order is nonprecedential

ORDER

Upon consideration of the November 17, 2011 order expediting briefing on the merits of this appeal, the motions to consolidate this appeal with forthcoming appeals, the motion for leave to file a corrected opening brief, the motion for leave to file public and confidential versions of its reply in support of its motion to stay the injunction, and the motions to amend the official caption to add Watson Pharma, Inc.,

IT IS ORDERED THAT:
(1) Oral argument for the merits of the appeal is scheduled to be held at 10 a.m., January 24, 2012, in Courtroom 201. The parties shall notify the clerk in writing of the name of the counsel who will present oral argument no later than January 9, 2012.
(2) The motions to consolidate will be granted and the official caption will be amended to add the appeal numbers from the district court's November 23, 2011 order denying their motion to dissolve the injunction and the district court's December 2, 2011 order denying their emergency motion for relief from the injunction, when those new appeals are docketed by this court.
(3) The motions to reform the caption are granted. Watson Pharma, Inc. is added to the caption. The revised official caption is reflected above.

http://www.leagle.com/xmlResult.aspx?xmldoc=In%20FCO%2020111206163.xml&docbase=CSLWAR3-2007-CURR


SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist